A Study in Adult and Pediatric Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this ascending dose group study is to assess the safety, tolerability, and
effects of multiple dose levels of INS37217 and placebo followed by five days twice daily
treatment with maximum tolerated dose administered by inhalation via the Pari LC Star
nebulizer in adult and pediatric patients with cystic fibrosis